Literature DB >> 11796616

Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.

Niklas Ahlborg1, Irene T Ling, Wendy Howard, Anthony A Holder, Eleanor M Riley.   

Abstract

Vaccination of mice with the 42-kDa region of Plasmodium yoelii merozoite surface protein 1 (MSP1(42)) or its 19-kDa C-terminal processing product (MSP1(19)) can elicit protective antibody responses in mice. To investigate if the 33-kDa N-terminal fragment (MSP1(33)) of MSP1(42) also induces protection, the gene segment encoding MSP1(33) was expressed as a glutathione S-transferase (GST) fusion protein. C57BL/6 and BALB/c mice were immunized with GST-MSP1(33) and subsequently challenged with the lethal P. yoelii YM blood stage parasite. GST-MSP1(33) failed to induce protection, and all mice developed patent parasitemia at a level similar to that in naive or control (GST-immunized) mice; mice immunized with GST-MSP1(19) were protected, as has been shown previously. Specific prechallenge immunoglobulin G (IgG) antibody responses to MSP1 were analyzed by enzyme-linked immunosorbent assay and immunofluorescence. Despite being unprotected, several mice immunized with MSP1(33) had antibody titers (of all IgG subclasses) that were comparable to or higher than those in mice that were protected following immunization with MSP1(19). The finding that P. yoelii MSP1(33) elicits strong but nonprotective antibody responses may have implications for the design of vaccines for humans based on Plasmodium falciparum or Plasmodium vivax MSP1(42).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796616      PMCID: PMC127676          DOI: 10.1128/IAI.70.2.820-825.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1.

Authors:  V Udhayakumar; D Anyona; S Kariuki; Y P Shi; P B Bloland; O H Branch; W Weiss; B L Nahlen; D C Kaslow; A A Lal
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

2.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

Authors:  Y P Shi; U Sayed; S H Qari; J M Roberts; V Udhayakumar; A J Oloo; W A Hawley; D C Kaslow; B L Nahlen; A A Lal
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

Authors:  J H Tian; L H Miller; D C Kaslow; J Ahlers; M F Good; D W Alling; J A Berzofsky; S Kumar
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

4.  Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds.

Authors:  A Egan; M Waterfall; M Pinder; A Holder; E Riley
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

Authors:  S Kumar; A Yadava; D B Keister; J H Tian; M Ohl; K A Perdue-Greenfield; L H Miller; D C Kaslow
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

6.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Authors:  S P Chang; S E Case; W L Gosnell; A Hashimoto; K J Kramer; L Q Tam; C Q Hashiro; C M Nikaido; H L Gibson; C T Lee-Ng; P J Barr; B T Yokota; G S Hut
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

7.  Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.

Authors:  T M Daly; C A Long
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

8.  Immunization against malaria with a recombinant protein.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1994-02       Impact factor: 2.280

9.  Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection.

Authors:  P A Burghaus; B T Wellde; T Hall; R L Richards; A F Egan; E M Riley; W R Ballou; A A Holder
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

10.  Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum.

Authors:  A F Egan; J A Chappel; P A Burghaus; J S Morris; J S McBride; A A Holder; D C Kaslow; E M Riley
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

View more
  22 in total

1.  Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.

Authors:  Sheetij Dutta; Deep C Kaushal; Lisa A Ware; Sunil K Puri; Nuzhat A Kaushal; Atul Narula; D S Upadhyaya; David E Lanar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  A comparative study of the genetic diversity of the 42kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax.

Authors:  M Andreina Pacheco; Amanda C Poe; William E Collins; Altaf A Lal; Kazuyuki Tanabe; Simon K Kariuki; Venkatachalam Udhayakumar; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2006-09-28       Impact factor: 3.342

3.  Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

Authors:  James R Alaro; Michele M Lynch; James M Burns
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

4.  Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.

Authors:  Ute Woehlbier; Christian Epp; Christian W Kauth; Rolf Lutz; Carole A Long; Boubacar Coulibaly; Bocar Kouyaté; Myriam Arevalo-Herrera; Sócrates Herrera; Hermann Bujard
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Authors:  Shigeto Yoshida; Hiroshi Nagumo; Takashi Yokomine; Hitomi Araki; Ayaka Suzuki; Hiroyuki Matsuoka
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

9.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

10.  Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Authors:  Simon J Draper; Anna L Goodman; Sumi Biswas; Emily K Forbes; Anne C Moore; Sarah C Gilbert; Adrian V S Hill
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.